Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Sanofi will pay $150 million upfront and up to $600 million in milestones for worldwide rights to MZE001, an oral drug from Maze Therapeutics in early…
The Federal Trade Commission has moved to block Sanofi's proposed licensing of MZE001 from Maze Therapeutics, arguing that Sanofi's dominant Pompe disease ERT…
Sanofi and Maze Therapeutics have terminated their $750 million licensing deal for the oral Pompe disease drug MZE001 after the US Federal Trade Commission…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Sanofi entered an exclusive worldwide license agreement for MZE001, an oral GYS1 inhibitor (oral substrate reduction therapy) for Pompe disease. Maze was to receive $150M cash upfront plus equity, with up to ~$600M in development/regulatory/commercial milestones (~$750M total). The U.S. FTC sued to block the deal in December 2023 as anticompetitive to Sanofi's Pompe ERT franchise; Sanofi terminated the agreement on Dec 11, 2023 and the FTC dismissed its challenge two days later. The asset was subsequently re-partnered: on May 10, 2024 Shionogi licensed MZE001 worldwide from Maze for $150M upfront plus development/regulatory/commercial milestones and tiered royalties — the same upfront Sanofi had offered, secured without antitrust overlap.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Maze Therapeutics, Inc. (this deal) | 2023 | $750M | — |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2023 deals · Sanofi SA deals · Rare Disease deals